XERS News and Press, Xeris Pharmaceuticals Inc. From 06/18/20

Xeris Pharmaceuticals (NASDAQ: XERS ) announces positive results from a Phase 2 clinical trial evaluating candidate XP-3924, a co-formulation of pramlintide and insulin, in adults with type 1 diabetes (T1D). More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on t...

XP-3924 resulted in a 62% reduction of hyperglycemia after a glucose challenge XP-3924 showed improved glucose control when compared to Humulin® R alone XP-3924 showed promising glucose control when compared to both Humulin® R and co-administered injections of Humulin&#x...

Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin Study achieved all pri...

Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-...

Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and com...

Xeris Pharmaceuticals ( XERS -6.4% ) enters into a non-exclusive agreement with unlicensed medicine distributor Clinigen Group plc for the supply and distribution of Gvoke (glucagon injection) outside of the U.S. on a "named patient" basis while its marketing application in Europe is und...

Xeris Pharmaceuticals (NASDAQ: XERS ) announces an exclusive agreement with Clinigen Group to manage the supply and distribution of Gvoke outside of U.S. where Gvoke is not currently licensed. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced an exclusive agreement with Clinigen Group plc (AIM: CLIN,...

SIFCO (NYSEMKT: SIF ) +61%  on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Image source: The Motley Fool. Xeris Pharmaceuticals, Inc.   (NASDAQ: XERS) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading